Adalimumab-associated optic neuritis

Jacob H. Chung; Gregory P. Van Stavern; Larry P. Frohman; Roger E. Turbin

doi:10.1016/j.jns.2006.01.012

Adalimumab-associated optic neuritis

Jacob H. Chung
, Gregory P. Van Stavern
, Larry P. Frohman
, Roger E. Turbin

Research output: Contribution to journal › Article › peer-review

85 Scopus citations

Abstract

We present, to our knowledge, the first published cases of optic neuritis associated with adalimumab, a medication in the class of anti-tumor necrosis factor-alpha (TNF-α) antagonists. Approved in recent years by the FDA, adalimumab (Humira, Abbott Laboratories; Abbott Park, IL) is a recombinant monoclonal antibody that targets and blocks the physiologic effects of TNF. Other TNF antagonists have had associations with optic neuritis and demyelinating events.

Original language	English
Pages (from-to)	133-136
Number of pages	4
Journal	Journal of the Neurological Sciences
Volume	244
Issue number	1-2
DOIs	https://doi.org/10.1016/j.jns.2006.01.012
State	Published - May 15 2006

Keywords

Adalimumab
Enbrel
Etanercept
Humira
Infliximab
Optic neuritis
Remicade
Tumor necrosis factor

Access to Document

10.1016/j.jns.2006.01.012

Cite this

@article{ead218cbe06a4165a10c23100798b1a1,

title = "Adalimumab-associated optic neuritis",

abstract = "We present, to our knowledge, the first published cases of optic neuritis associated with adalimumab, a medication in the class of anti-tumor necrosis factor-alpha (TNF-α) antagonists. Approved in recent years by the FDA, adalimumab (Humira, Abbott Laboratories; Abbott Park, IL) is a recombinant monoclonal antibody that targets and blocks the physiologic effects of TNF. Other TNF antagonists have had associations with optic neuritis and demyelinating events.",

keywords = "Adalimumab, Enbrel, Etanercept, Humira, Infliximab, Optic neuritis, Remicade, Tumor necrosis factor",

author = "Chung, \{Jacob H.\} and \{Van Stavern\}, \{Gregory P.\} and Frohman, \{Larry P.\} and Turbin, \{Roger E.\}",

note = "Funding Information: This work was supported in part by an Unrestricted Grant from Research to Prevent Blindness, Inc. NY, NY; Fund for the New Jersey Blind, Newark, NJ; Lions Eye Research Foundation of New Jersey, Newark, NJ; the Eye Institute of New Jersey, Newark, NJ; and the Gene C. Coppa Memorial Fund. ",

year = "2006",

month = may,

day = "15",

doi = "10.1016/j.jns.2006.01.012",

language = "English",

volume = "244",

pages = "133--136",

journal = "Journal of the Neurological Sciences",

issn = "0022-510X",

number = "1-2",

}

TY - JOUR

T1 - Adalimumab-associated optic neuritis

AU - Chung, Jacob H.

AU - Van Stavern, Gregory P.

AU - Frohman, Larry P.

AU - Turbin, Roger E.

N1 - Funding Information: This work was supported in part by an Unrestricted Grant from Research to Prevent Blindness, Inc. NY, NY; Fund for the New Jersey Blind, Newark, NJ; Lions Eye Research Foundation of New Jersey, Newark, NJ; the Eye Institute of New Jersey, Newark, NJ; and the Gene C. Coppa Memorial Fund.

PY - 2006/5/15

Y1 - 2006/5/15

N2 - We present, to our knowledge, the first published cases of optic neuritis associated with adalimumab, a medication in the class of anti-tumor necrosis factor-alpha (TNF-α) antagonists. Approved in recent years by the FDA, adalimumab (Humira, Abbott Laboratories; Abbott Park, IL) is a recombinant monoclonal antibody that targets and blocks the physiologic effects of TNF. Other TNF antagonists have had associations with optic neuritis and demyelinating events.

AB - We present, to our knowledge, the first published cases of optic neuritis associated with adalimumab, a medication in the class of anti-tumor necrosis factor-alpha (TNF-α) antagonists. Approved in recent years by the FDA, adalimumab (Humira, Abbott Laboratories; Abbott Park, IL) is a recombinant monoclonal antibody that targets and blocks the physiologic effects of TNF. Other TNF antagonists have had associations with optic neuritis and demyelinating events.

KW - Adalimumab

KW - Enbrel

KW - Etanercept

KW - Humira

KW - Infliximab

KW - Optic neuritis

KW - Remicade

KW - Tumor necrosis factor

UR - https://www.scopus.com/pages/publications/33646089875

U2 - 10.1016/j.jns.2006.01.012

DO - 10.1016/j.jns.2006.01.012

M3 - Article

C2 - 16527311

AN - SCOPUS:33646089875

SN - 0022-510X

VL - 244

SP - 133

EP - 136

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

IS - 1-2

ER -

Adalimumab-associated optic neuritis

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this